Advanced Malignancies

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

Clinical Study of BR105 Injection

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

A Study of BR111 in Patients With Advanced Malignancies

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Phase I/II Clinical Study of 1A46 Drug Substance